Skip to content

Cannabis: all studies

Page 230 of 287: studies 2,291 to 2,300 of 2,868, newest first. Back to the cannabis overview

Research

Cannabinoid CB1 Receptors Are Expressed in a Subset of Dopamine Neurons and Underlie Cannabinoid-Induced Aversion, Hypoactivity, and Anxiolytic Effects in Mice.

Journal of Neuroscience January 18, 2023 Xiao Han, Ying Liang, Briana J. Hempel et al.

Cannabinoids modulate dopamine (DA) transmission and DA-related behavior, which has been thought to be mediated initially by activation of cannabinoid CB1 receptors (CB1Rs) on GABA neurons. However, there is no behavioral evidence supporting it. In contrast, here we report that CB1Rs are also expressed in a subset of DA neurons and functionally underlie cannabinoid action in male and female...

Indigenous-Amazonian Traditional Medicine’s Usage of the Tobacco Plant: A Transdisciplinary Ethnopsychological Mixed-Methods Case Study

Plants January 11, 2023 Ilana Berlowitz, Ernesto García Torres, Caroline Maake et al. 14 citations

Harmful usage of tobacco is a global public health problem associated with adverse health effects and addiction. Yet, in the Peruvian Amazon, the native region of Nicotiana rustica L., this plant is used in remarkably different manners: it is considered a potent medicinal plant, applied in liquid form for oral ingestion to treat mental health problems, a common and ancient healing practice in...

Hexahydrocannabinol Pharmacology, Toxicology, and Analysis: The First Evidence for a Recent New Psychoactive Substance.

Current Neuropharmacology 2023 Silvia Graziano, Maria Rosaria Varì, Simona Pichini et al.

During the last two years, hexahydrocannabinol (HHC), the hydrogenated derivative of tetrahydrocannabinol has been freely sold by internet websites as a "legal" replacement to THC and cannabis in a range of highly attractive branded and unbranded products, some of which are sold as "legal highs". Potentially, there could be a large demand for HHC products by individuals in Europe and...

DOI: 10.2174/1570159x21666230623104624 (opens in new tab) Full text (opens in new tab) Hexahydrocannabinol New psychoactive substances Phytocannabinoids Synthetic cannabinoids

Development and initial validation of an MDMA/Ecstasy motives assessment.

Addictive Behaviors 2023 James E Sottile, Kathryn S Macia, Robert E Wickham et al.

MDMA/Ecstasy motives differ from those of other substances such as alcohol, cannabis, and methamphetamine. Previous literature on alcohol and cannabis use identified social, expansion, enhancement, coping, and conformism as primary motives for use. MDMA/Ecstasy users also report using the drug for increases in self-awareness and energy. The development of an MDMA/Ecstasy use motives assessment...

Intoxication in the Ancient Greek and Roman World

Lexington Books 2023 A. Sumler 2 citations

Intoxication in the Ancient Greek and Roman World considers the psychotropic plants used in the ancient world and ancient attitudes towards intoxication. Alan Sumler surveys primary Greek and Roman sources for noteworthy mentions of ancient intoxicants like hellebore, mandrake, deadly nightshade, thorn apple, opium poppy, cannabis, wine, and other substances and reveals how psychoactive drugs...

The Global Distribution and Epidemiology of Psychoactive Substance Use and Injection Drug Use Among Street-Involved Children and Youth: A Meta-Analysis.

Substance Use & Misuse 2023 Bahram Armoon, Mark D Griffiths, Rasool Mohammadi 13 citations

Background: Globally, street-involved children and youth (SICY) who work and live on/of the streets are at higher risk of increased psychoactive substances and injecting drug use. Objectives: The present study aimed to identify the prevalence, distribution, sociodemographic factors, and risk-taking behaviors associated with psychoactive substances and injecting drug use among SICY. Methods:...

DOI: 10.1080/10826084.2023.2181036 (opens in new tab) Full text (opens in new tab) Casual sex partner Injection drug use Psychoactive substances Sex trade +6

Use of Selective Alternative Therapies for Treatment of OCD.

Neuropsychiatric Disease and Treatment 2023 Iman Khan, Taimoor Asif Jaura, Alaa Tukruna et al. 5 citations

About 40% of the people with the obsessive-compulsive-disorder do not experience the desired outcome after the existing treatment, and its several side effects were reported. This systematic review was conducted to evaluate the efficacy and tolerability of alternative drugs and assess the possibility of their use as treatment options for obsessive-compulsive-disorder. The Scientific databases...

The thalamus in psychosis spectrum disorder.

Frontiers in Neuroscience 2023 Alan Anticevic, Michael M. Halassa 41 citations

Psychosis spectrum disorder (PSD) affects 1% of the world population and results in a lifetime of chronic disability, causing devastating personal and economic consequences. Developing new treatments for PSD remains a challenge, particularly those that target its core cognitive deficits. A key barrier to progress is the tenuous link between the basic neurobiological understanding of PSD and its...

DOI: 10.3389/fnins.2023.1163600 (opens in new tab) Full text (opens in new tab) Cognition Computation Functional connectivity Pharmacology +4

Use of psychoactive substances by goods carriage drivers associated with Kerala, India.

Traffic injury prevention 2023 M S Siva Prasad, C V Priyatha, Jayesh K Joseph et al.

This study aimed to measure the prevalence of drugs of abuse (DOA) among the goods carriage drivers associated with the southern State of India, Kerala. Point-of-collection testing (POCT) of oral fluid collected from the participants (n = 249) was done using the Evidence MultiSTAT DOA Oral Fluid II Assay kits and the Evidence MultiSTAT analyzer. Out of the total samples, 53 (21.29%) were...

DOI: 10.1080/15389588.2023.2246163 (opens in new tab) Full text (opens in new tab) New psychoactive substances Bio-chip array technology Drivers Point-of-collection testing +4

Systematic use of LSD, mephedron and amanita muscaria without signs mental and addictive pathology. The case of Daria D.

Neurology Bulletin December 24, 2022 Vladimir D. Mendelevich, Veronika N. Konovalova, Galya M. Galiullina et al.

The article describes the case of Daria D., 23 years old, who has been using various drugs (LSD, marijuana, mephedrone) for a number of years and independently abandoned using drags with the transition to the use of microdoses of red fly agaric (Amanita Muskaria). Her mental and addictive status is analyzed. It is concluded that, despite the systematic use of drugs, there are no grounds for...